Incidence of liver injury among cancer patients receiving chemotherapy in an integrated health system

Yood, Marianne Ulcickas; Bortolini, M.; Casso, Deborah; Beck, Jean G.; Oliveria, Susan A.; Wells, Karen; Woodcroft, Kimberley J.; Wang, Lisa I.

doi:10.1002/pds.3757

Cited by 15 publications

(12 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies from Asia or Australia were published in more recent years. Majority of the studies included adult populations (62%), two studies (7%) included children aged 18 years and below, eight studies (28%) included a mixed adult and children population, while age limit was not reported in one study . Apart from two prospective studies with shorter study periods, the rest of the studies were conducted retrospectively.…”

Section: Resultsmentioning

confidence: 99%

“…With respect to reporting quality, selection criteria and detection algorithm were generally well‐reported, with the exception of two studies which did not list out the specific diagnosis codes. Eleven studies did not report the expertise of adjudicators in confirming the DILI cases. Only seven studies performed well in generalizability.…”

Section: Resultsmentioning

confidence: 99%

“…Of the studies that did not use diagnosis codes, only four studies specified drugs of interest. Three of these studies performed better than the others, except one study, which assessed Hy's Law in chemotherapy patients. The population of patients was dissimilar to the other studies because the most common false positive was because of liver metastases.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Systematic review and meta‐analysis of algorithms used to identify drug‐induced liver injury (DILI) in health record databases

Tan

Low

Dan

et al. 2017

Liver International

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Systematic review and meta‐analysis of algorithms used to identify drug‐induced liver injury (DILI) in health record databases

Tan

Low

Dan

et al. 2017

Liver International

View full text Add to dashboard Cite

show abstract

“…As such, it is not the only causality tool employed by the DILIN, which has created its own additional criteria based on expert opinion incorporated into RUCAM, as illustrated in Table 5[59,118]. Even with more accurate causality tools, the clinical problems in diagnosing DILI in the setting of underlying CLD[69,72], malignancy[119], or congestive heart failure[120] still rests heavily on physician’s expertise which cannot easily be substituted by scoring systems[60,69]; a fact which is even more relevant in the face of HILI, because of the unknown and unregulated ingredients often incorporated into HDS[73], again indicating the need for future research in this field[121]. …”

Section: Diagnosing and Establishing Causalitymentioning

confidence: 99%

Drug-induced liver injury: Do we know everything?

Alempijević

Zec

Milosavljević

2017

WJH

View full text Add to dashboard Cite

Interest in drug-induced liver injury (DILI) has dramatically increased over the past decade, and it has become a hot topic for clinicians, academics, pharmaceutical companies and regulatory bodies. By investigating the current state of the art, the latest scientific findings, controversies, and guidelines, this review will attempt to answer the question: Do we know everything? Since the first descriptions of hepatotoxicity over 70 years ago, more than 1000 drugs have been identified to date, however, much of our knowledge of diagnostic and pathophysiologic principles remains unchanged. Clinically ranging from asymptomatic transaminitis and acute or chronic hepatitis, to acute liver failure, DILI remains a leading causes of emergent liver transplant. The consumption of unregulated herbal and dietary supplements has introduced new challenges in epidemiological assessment and clinician management. As such, numerous registries have been created, including the United States Drug-Induced Liver Injury Network, to further our understanding of all aspects of DILI. The launch of LiverTox and other online hepatotoxicity resources has increased our awareness of DILI. In 2013, the first guidelines for the diagnosis and management of DILI, were offered by the Practice Parameters Committee of the American College of Gastroenterology, and along with the identification of risk factors and predictors of injury, novel mechanisms of injury, refined causality assessment tools, and targeted treatment options have come to define the current state of the art, however, gaps in our knowledge still undoubtedly remain.

show abstract

“…In previous years, combined chemotherapy has been proved to be an import way in increasing the efficacy of the treatment of hepatocarcinoma ( 4 ) and cisplatin treatment combined with specific molecular targeted drug has attracted increased attention. As an oral antidiabetic drug, metformin is the first-line drug for the treatment of type 2 diabetes.…”

Section: Introductionmentioning

confidence: 99%

Metformin enhances the chemosensitivity of hepatocarcinoma cells to cisplatin through AMPK pathway

Dong

Huang

Zheng³

et al. 2017

Oncol Lett

View full text Add to dashboard Cite

This study investigated the effect of metformin on chemosensitivity of hepatocarcinoma cells to cisplatin and the possible mechanism. HepG2 and Huh-7 hepatoma cells were treated with cisplatin at concentrations of 0, 2, 4, 6, 8 and 10 µM for 48 h. Proliferation of HepG2 and Huh-7 hepatoma cells were detected by MTT assay. Apoptosis of hepatocellular carcinoma cells was detected by flow cytometry. Western blot analysis was used to detect the expression of 5-monophosphate-activated protein kinase (AMPK) and p-AMPK protein. Proliferative activity of HepG2 and Huh-7 cells decreased with the increase of cisplatin concentration. After adding metformin, proliferation ability of hepatocarcinoma cells was significantly reduced. Apoptosis rate of the metformin was significantly higher than that of the control group, and apoptosis rate of the cisplatin + metformin was significantly higher than that of the cisplatin group. There was no significant difference in expression level of AMPK protein found between control, metformin, cisplatin and cisplatin + metformin group. Compared with the control, ratio of p-AMPK/AMPK in metformin group was increased, and ratio of p-AMPK/AMPK in cisplatin + metformin was significantly higher than that in cisplatin group. Activity of cells in cisplatin + metformin + compound C (AMPK pathway blocker) group was significantly higher than that of cisplatin + metformin, while apoptosis of cells in cisplatin + metformin + compound C (AMPK pathway blocker) was significantly lower than that of cisplatin + metformin group. In conclusion, metformin can inhibit the proliferation, promote apoptosis and enhance the chemosensitivity of hepatocarcinoma cells to cisplatin through AMPK pathway.

show abstract

Incidence of liver injury among cancer patients receiving chemotherapy in an integrated health system

Cited by 15 publications

References 17 publications

Systematic review and meta‐analysis of algorithms used to identify drug‐induced liver injury (DILI) in health record databases

Systematic review and meta‐analysis of algorithms used to identify drug‐induced liver injury (DILI) in health record databases

Drug-induced liver injury: Do we know everything?

Metformin enhances the chemosensitivity of hepatocarcinoma cells to cisplatin through AMPK pathway

Contact Info

Product

Resources

About